ARGX — argenx SE

Summary of ARGX Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Product Net Sales: $1.3 billion, consistent with prior guidance.
• Full Year 2025 Product Net Sales: $4.2 billion, representing a 90% year-over-year growth.
• U.S. Revenue: $1.1 billion in Q4, a 68% increase year-over-year.
• Operating Profit: $367 million for Q4 and $1.1 billion for the full year, marking the company’s first year of annual operating profitability.
• Total Operating Expenses: $955 million for Q4, with R&D and SG&A expenses totaling $2.7 billion for the year.
• Cash Position: $4.4 billion at the end of Q4, an increase of over $1 billion from the previous year.

2. Strategic Updates and Business Highlights

• Patient Reach: VYVGART has reached 19,000 patients globally, aided by the launch of a prefilled syringe for self-injection.
• Pipeline Development: Four new molecules from the immunology pipeline were introduced, with a goal of at least one new pipeline candidate per year.
• ADAPT OCULUS Study: Positive results were reported for VYVGART in ocular myasthenia gravis (MG), leading to plans for an sBLA submission to the FDA.
• Expansion Plans: Focus on expanding VYVGART's indications to include seronegative MG and ocular MG, targeting a total addressable population of approximately 60,000 patients in the U.S.
• CIDP Growth: Continued efforts to expand the CIDP patient population beyond the initial 12,000 patients, with a focus on increasing prescriber adoption.

3. Forward Guidance and Outlook

• 2026 Expectations: Operating expenses are expected to grow at a similar rate as in previous years, primarily driven by R&D investments.
• Revenue Growth: Anticipated sustained growth in both MG and CIDP markets, with ongoing efforts to expand into new patient populations and indications.
• PDUFA Dates: The PDUFA date for seronegative MG is set for May 10, 2026, with expectations of a similar timeline for ocular MG following the sBLA submission.

4. Challenges and Points of Concern

• Market Competition: Emerging competition in the MG space may impact VYVGART's market share, although management remains confident in its product profile.
• Regulatory Hurdles: The need for two pivotal trials for the Graves program may delay progress.
• Q1 Dynamics: Seasonal factors, such as winter storms and reverifications, may affect patient starts and sales in Q1 2026, similar to previous years.

5. Notable Q&A Insights

• Pricing Strategy: Expected pricing for new indications (seronegative and ocular MG) is anticipated to be similar to current MG pricing at approximately $225,000 net.
• CIDP Adoption: There is a gradual increase in CIDP patient adoption, with 85% of patients switching from IVIg, and a focus on expanding use beyond this group.
• Impact of Ocular MG Approval: Approval in ocular MG is expected to drive earlier utilization in less advanced MG patients, potentially preventing progression to generalized disease.
• Clinical Significance of Ocular MG Data: The study showed a statistically significant improvement in patient-reported outcomes, with a p-value of 0.012, indicating a meaningful clinical benefit.

This summary encapsulates the key aspects of the earnings call, highlighting ARGX's financial performance, strategic initiatives, future outlook, and challenges faced in the competitive landscape.